🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

DAratumumab and REvlimid REfractory MM

Recruitingn/aAges 18 Years - anyAllFondazione IRCCS Policlinico San Matteo di Pavia
NCT06541860 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Phase I * Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme * Patients aged ≥ 18 years * Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data Phase II * Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes * Patients aged ≥ 18 years * Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data Exclusion Criteria: * Patients not willing to consent to review of clinical data
💊

What it tests

  • Not listed
📍

Where

1 site
Irccs San Matteo Pavia
Pavia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy